Low expression of organic anion-transporting polypeptide 1B3 predicts a poor prognosis in hepatocellular carcinoma

Abstract

Objective: To detect the expression level of organic anion-transporting polypeptide 1B3 (OATP1B3) in hepatocellular carcinoma (HCC) and to determine the relationship between OATP1B3 expression, clinicopathological features, and prognosis. Methods: Immunohistochemical (IHC) staining was performed to detect the expression of OATP1B3 in 131 HCC specimens and in 89 adjacent nontumorous tissues. Moreover, the expression levels of OATP1B3 in 30 pairs of tumor and matched adjacent nontumorous tissues were detected by quantitative real-time polymerase chain reaction, and 34 pairs of tumor and matched adjacent nontumorous tissues were detected by Western blotting. The χ 2 test was applied to analyze the correlation between OATP1B3 expression and the clinical parameters of HCC patients. The prognostic value of OATP1B3 in HCC patients was estimated by Kaplan-Meier survival analysis and the Cox stepwise proportional hazards model. Results: Compared with that in adjacent nontumorous tissues (25.8%, 23/89), OATP1B3 expression was significantly downregulated in tumor tissues (59.5%, 78/131) (P < 0.0001). Moreover, OATP1B3 expression was markedly correlated with tumor size, recurrence, tumor differentiation, and tumor node metastasis (TNM) stage (P < 0.05 for each). However, age, sex, tumor capsule status, HBsAg, cirrhosis, tumor number, vascular invasion, and serum alpha fetoprotein were not associated with OATP1B3 expression. The overall survival (OS) and disease-free survival (DFS) of HCC patients who had high expression of OATP1B3 were significantly longer than those of patients with low expression (33.0% vs 12.9%, P = 0.001; 18.8% vs 5.3%, P < 0.0001). Cox multivariate analysis showed that OATP1B3, invasion, and TNM stage (P < 0.05 for each) were independent prognostic factors of OS in HCC patients and that OATP1B3 and TNM stage (both P < 0.05) were independent prognostic factors of DFS in HCC patients. Conclusions: The expression of OATP1B3 in HCC patients was significantly lower than that in adjacent nontumorous tissues. OATP1B3 expression may be a potential prognostic marker in HCC patients.

Risk predictive model based on three immune-related gene pairs to assess prognosis and therapeutic sensitivity for hepatocellular carcinoma

“…HCC comprises 75-85% of liver cancers and has a poor prognosis [1]. Some studies have shown multiple genes present good predictive potential in assessing HCC prognosis [15][16][17][18]. Recently, the importance of ICI therapy in HCC patients has been proven.…”

“…Generally speaking, a model with more genes and gene pairs will attain a higher AUC of OS. Second, our model did not include some earlier reported HCC prognosis genes [15][16][17][18]. Our prediction model only included 3 immune-related gene pairs with 6 genes to assess both the prognosis and treatment sensitivity to immune and targeted therapy of HCC patients, and it was hard to include all genes reported.…”

N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma

“…HCC accounts for 75–85% of liver cancers and is also the third leading cause of cancer-related death globally, which has a poor prognosis [ 1 ]. Studies have shown that multiple genes play an important role in HCC progression [ 30 – 34 ]. Currently, immunotherapy has already become a viable option for advanced patients.…”

Effects of the SLCO1B1 A388G single nucleotide polymorphism on the development, clinical parameters and survival of multiple myeloma cases in a Polish population

“…Recently, Chen et al showed that the OATP1B3 expression was signi cantly reduced in neoplastic tissues compared to that in adjacent non-neoplastic tissues. Moreover, the OATP1B3 lower expression was signi cantly correlated with the tumor size, relapse, tumor differentiation, and tumor node metastasis (TNM) rate in hepatocellular carcinoma 39 .…”